Indian court lifts stay on Cipla's generic Sutent; firm slashes prices of anticancers
This article was originally published in Scrip
Executive Summary
The Supreme Court of India has lifted a lower court stay against Cipla in a case concerning the potential launch of its cut-price generic version of Pfizer's anticancer, Sutent (sunitinib malate). The court action came on a day that also saw Cipla announce massive price cuts for three of its other generic anticancers.